Patents by Inventor Stefan Scheuerer

Stefan Scheuerer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF
    Publication number: 20240109909
    Abstract: The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD.
    Type: Application
    Filed: July 31, 2023
    Publication date: April 4, 2024
    Inventors: Heiner Ebel, Sara Frattini, Kai Gerlach, Riccardo Giovannini, Christoph Hoenke, Rocco Mazzaferro, Marco Santagostino, Stefan Scheuerer, Christofer Tautermann, Thomas Trieselmann
  • CCR2 receptor antagonists and uses thereof
    Patent number: 11731981
    Abstract: The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD.
    Type: Grant
    Filed: June 11, 2021
    Date of Patent: August 22, 2023
    Assignee: Centrexion Therapeutics Corporation
    Inventors: Heiner Ebel, Sara Frattini, Kai Gerlach, Riccardo Giovannini, Christoph Hoenke, Rocco Mazzaferro, Marco Santagostino, Stefan Scheuerer, Christofer Tautermann, Thomas Trieselmann
  • N-(2,2-difluoroethyl)-N-[(pyrimidinylamino)propanyl]arylcarboxamides
    Patent number: 11324724
    Abstract: The present invention relates to novel N-(2,2-difluoroethyl)-N-[(Pyrimidinylamino)propanyl]-arylcarboxamide derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment or prevention of conditions having an association with the orexin sub-type 1 receptor.
    Type: Grant
    Filed: September 26, 2018
    Date of Patent: May 10, 2022
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Doris Riether, Niklas Heine, Uta Friederike Lessel, Stefan Scheuerer
  • N-[(pyrimidinylamino)propanyl]-,n-[pyridylamino)propanyl]- and n-[(pyrazinylaminol)propanyl]arylcarboxamides
    Patent number: 11236072
    Abstract: The present invention relates to novel N-[(Pyrimidinylamino)propanyl]-, N-[(Pyridylamino)-propanyl]- and N-[(Pyrazinylamino)¬propanyl]arylcarboxamide such as compound The present invention also relates to derivatives of such compounds, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment or prevention of conditions having an association with the orexin sub-type 1 receptor.
    Type: Grant
    Filed: July 26, 2018
    Date of Patent: February 1, 2022
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Doris Riether, Marco Ferrara, Niklas Heine, Uta Friederike Lessel, Radoslaw Lipinski, Stefan Scheuerer
  • CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF
    Publication number: 20220002310
    Abstract: The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD.
    Type: Application
    Filed: June 11, 2021
    Publication date: January 6, 2022
    Inventors: Heiner Ebel, Sara Frattini, Kai Gerlach, Riccardo Giovannini, Christoph Hoenke, Rocco Mazzaferro, Marco Santagostino, Stefan Scheuerer, Christofer Tautermann, Thomas Trieselmann
  • CCR2 receptor antagonists and uses thereof
    Patent number: 11046706
    Abstract: The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD.
    Type: Grant
    Filed: December 27, 2018
    Date of Patent: June 29, 2021
    Assignee: Centrexion Therapeutics Corporation
    Inventors: Heiner Ebel, Sara Frattini, Kai Gerlach, Riccardo Giovannini, Christoph Hoenke, Rocco Mazzaferro, Marco Santagostino, Stefan Scheuerer, Christofer Tautermann, Thomas Trieselmann
  • NOVEL N-(2,2-DIFLUOROETHYL)-N-[(PYRIMIDINYLAMINO)PROPANYL]ARYLCARBOXAMIDES
    Publication number: 20200283418
    Abstract: The present invention relates to novel N-(2,2-difluoroehtyl)-N-[(Pyrimidinylamino)propanyl]-arylcarboxamide derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment or prevention of conditions having an association with the orexin sub-type 1 receptor.
    Type: Application
    Filed: September 26, 2018
    Publication date: September 10, 2020
    Inventors: Doris RIETHER, Niklas HEINE, Uta Friederike LESSEL, Stefan SCHEUERER
  • NOVEL N-[(PYRIMIDINYLAMINO)PROPANYL]-,N-[PYRIDYLAMINO)PROPANYL]- AND N-[(PYRAZINYLAMINOL)PROPANYL]ARYLCARBOXAMIDES
    Publication number: 20200231575
    Abstract: The present invention relates to novel N-[(Pyrimidinylamino)propanyl]-, N-[(Pyridylamino)propanyl]- and N-[(Pyrazinylamino)propanyl]arylcarboxamide derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment or prevention of conditions having an association with the orexin sub-type 1 receptor.
    Type: Application
    Filed: July 26, 2018
    Publication date: July 23, 2020
    Inventors: Doris RIETHER, Marco FERRARA, Niklas HEINE, Uta Friederike LESSEL, Radoslaw LIPINSKI, Stefan SCHEUERER
  • N-[(Pyrimidinylamino)propanyl]-and N-[(Pyridinylamino)-propanyl]arylcarboxamides
    Patent number: 10710984
    Abstract: The present invention relates to novel N-[(Pyrimidinylamino)propanyl]- and N-[(Pyridinylamino)propanyl]arylcarboxamide derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment or prevention of conditions having an association with the orexin sub-type 1 receptor.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: July 14, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Doris Riether, Marco Ferrara, Niklas Heine, Uta Lessel, Janet Rachel Nicholson, Anton Pekcec, Stefan Scheuerer
  • CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF
    Publication number: 20190300541
    Abstract: The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD.
    Type: Application
    Filed: December 27, 2018
    Publication date: October 3, 2019
    Inventors: Heiner Ebel, Sara Frattini, Kai Gerlach, Riccardo Giovannini, Christoph Hoenke, Rocco Mazzaferro, Marco Santagostino, Stefan Scheuerer, Christofer Tautermann, Thomas Trieselmann
  • Novel N-[(Pyrimidinylamino)Propanyl]-and N-[(Pyridinylamino)Propanyl]Arylcarboxamides
    Publication number: 20190112297
    Abstract: The present invention relates to novel N-[(Pyrimidinylamino)propanyl]- and N-[(Pyridinylamino)propanyl]arylcarboxamide derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment or prevention of conditions having an association with the orexin sub-type 1 receptor.
    Type: Application
    Filed: April 7, 2017
    Publication date: April 18, 2019
    Inventors: Doris RIETHER, Marco FERRARA, Niklas HEINE, Uta LESSEL, Janet Rachel NICHOLSON, Anton PEKCEC, Stefan SCHEUERER
  • CCR2 receptor antagonists and uses thereof
    Patent number: 10196402
    Abstract: The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: February 5, 2019
    Assignee: Centrexion Therapeutics Corporation
    Inventors: Heiner Ebel, Sara Frattini, Kai Gerlach, Riccardo Giovannini, Christoph Hoenke, Rocco Mazzaferro, Marco Santagostino, Stefan Scheuerer, Christofer Tautermann, Thomas Trieselmann
  • N-[(pyrimidinylamino)propanyl]-and N[(pyrazinylamino)proppanyl]arylcarboxamides
    Patent number: 9884854
    Abstract: The present invention relates to novel N-[(Pyrimidinylamino)propanyl]- and N-[(Pyrazinylamino)-propanyl]arylcarboxamide derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment or prevention of conditions having an association with the orexin sub-type 1 receptor.
    Type: Grant
    Filed: April 12, 2017
    Date of Patent: February 6, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Doris Riether, Marco Ferrara, Niklas Heine, Uta Friederike Lessel, Janet Rachel Nicholson, Anton Pekcec, Stefan Scheuerer
  • NEW CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF
    Publication number: 20170362249
    Abstract: The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD.
    Type: Application
    Filed: May 26, 2017
    Publication date: December 21, 2017
    Inventors: Heiner Ebel, Sara Frattini, Kai Gerlach, Riccardo Giovannini, Christoph Hoenke, Rocco Mazzaferro, Marco Santagostino, Stefan Scheuerer, Christofer Tautermann, Thomas Trieselmann
  • NOVEL N-[(PYRIMIDINYLAMINO)PROPANYL]-AND N [(PYRAZINYLAMINO)PROPANYL]ARYLCARBOXAMIDES
    Publication number: 20170298053
    Abstract: The present invention relates to novel N-[(Pyrimidinylamino)propanyl]- and N-[(Pyrazinylamino)-propanyl]arylcarboxamide derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment or prevention of conditions having an association with the orexin sub-type 1 receptor.
    Type: Application
    Filed: April 12, 2017
    Publication date: October 19, 2017
    Inventors: Doris RIETHER, Marco FERRARA, Niklas HEINE, Uta Friederike LESSEL, Janet Rachel NICHOLSON, Anton PEKCEC, Stefan SCHEUERER
  • CCR2 receptor antagonists and uses thereof
    Patent number: 9670222
    Abstract: The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD.
    Type: Grant
    Filed: April 24, 2014
    Date of Patent: June 6, 2017
    Assignee: Centrexion Therapeutics Corporation
    Inventors: Heiner Ebel, Sara Frattini, Kai Gerlach, Riccardo Giovannini, Christoph Hoenke, Rocco Mazzaferro, Marco Santagostino, Stefan Scheuerer, Christofer Tautermann, Thomas Trieselmann
  • 6,7,8,9-tetrahydro-5H-1,4,7,10a-tetraaza-cyclohept[f]indene derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them
    Patent number: 9346816
    Abstract: The present invention relates to compounds defined by formula I wherein the groups X, Y, W and R1 to R4 are defined as in claim 1, possessing valuable pharmacological activity. Particularly the compounds are agonists of the 5-HT2C receptor, and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this receptor, such as metabolic and CNS-related disorders.
    Type: Grant
    Filed: November 5, 2013
    Date of Patent: May 24, 2016
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Stephan-Georg Mueller, Christopher John Brown, Alexander Heifetz, Bernd Nosse, Juergen Prestle, Natacha Prevost, Klaus Rudolf, Stefan Scheuerer, Marcus Schindler, Dirk Stenkamp, Leo Thomas, Heather Tye
  • Selective CCR2 antagonists
    Patent number: 9108958
    Abstract: The present invention relates to novel and selective antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD as well as pain.
    Type: Grant
    Filed: July 13, 2012
    Date of Patent: August 18, 2015
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Heiner Ebel, Sara Frattini, Riccardo Giovannini, Stefan Scheuerer
  • Pyridazine carboxamides as CCR2 receptor antagonists
    Patent number: 9018212
    Abstract: The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD.
    Type: Grant
    Filed: May 23, 2011
    Date of Patent: April 28, 2015
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Heiner Ebel, Sara Frattini, Riccardo Giovannini, Christoph Hoenke, Stefan Scheuerer
  • CCR2 antagonists
    Patent number: 8962656
    Abstract: The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) of formula (Ia) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD.
    Type: Grant
    Filed: May 26, 2011
    Date of Patent: February 24, 2015
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Heiner Ebel, Sara Frattini, Riccardo Giovannini, Christoph Hoenke, Stefan Scheuerer